Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Condition:   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: Pembrolizumab;   Drug: IO102-103 Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   IO Biotech;   Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials